ArticleFrontiers in oncology2022

Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma.

Colin Thomas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.